GLSI
Greenwich Lifesciences
$13.44
+$0.46 (+3.54%)Jul 27, 2026
Key metrics
The numbers that frame GLSI today
- Market cap
- $197.28M
- P/E (TTM)
- -9.1
- EV / FCF
- -14.6
- ROIC
- 605.7%
- Div yield
- 0%
- Debt / equity
- 0.0
- 52wk Low
- $7.78
- 52wk High
- $34.10
Growth
Revenue and earnings trend for GLSI
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about GLSI
Is Greenwich Lifesciences a good buy?
Hold. Greenwich Lifesciences has excellent momentum, but poor quality makes the setup mixed. Growth looks poor. That could put pressure on the long-term business case. We think Greenwich Lifesciences is selling at a very high price.
What is the market capitalization of GLSI?
Greenwich Lifesciences's market capitalization is $197.28M.
What is the P/E ratio for GLSI stock?
Greenwich Lifesciences's current P/E ratio is -9.1.
What is the 52-week high for GLSI stock?
The 52-week high for Greenwich Lifesciences is $34.10. The current close of $13.44 is 60.6% below that high.
What is the 52-week low for GLSI stock?
The 52-week low for Greenwich Lifesciences is $7.78. The current close of $13.44 is 72.8% above that low.
Does GLSI stock pay dividends?
Greenwich Lifesciences does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for GLSI?
Greenwich Lifesciences's Debt / Equity ratio is 0.